In:
Journal of the National Comprehensive Cancer Network, Harborside Press, LLC, Vol. 18, No. 4 ( 2020-04), p. 452-478
Abstract:
Several new systemic therapy options have become available for patients with metastatic breast cancer, which have led to improvements in survival. In addition to patient and clinical factors, the treatment selection primarily depends on the tumor biology (hormone-receptor status and HER2-status). The NCCN Guidelines specific to the workup and treatment of patients with recurrent/stage IV breast cancer are discussed in this article.
Type of Medium:
Online Resource
ISSN:
1540-1405
,
1540-1413
DOI:
10.6004/jnccn.2020.0016
Language:
Unknown
Publisher:
Harborside Press, LLC
Publication Date:
2020
Permalink